Revive Therapeutics Announces Research Collaboration For Natural Psilocybin Biosynthesis

Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a sponsored research collaboration agreement, as well as an exclusive option to license agreement, with that of the North Carolina State University. The arrangements are focused on developing a novel biosynthetic version of psilocybin.

The biosynthetic version of psilocybin is said to be based on a natural biosynthetic enzymatic platform, which was developed by Dr Gavin Williams, a professor at researcher at North Carolina State University. The platform is said to have the potential of providing a “simple and efficient method for rapidly producing natural products, such as psilocybin.”

The tech reportedly works via the use of an engineered enzyme pathway in E. coli. The science is based on the development of an artificial enzymatic platform that has been named the “Alcohol Dependent Hemiterpene,” with the pathway reportedly used as a key building block for psilocybin and its derivatives.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

If successful, Revive has identified that it intends to develop and commercialize its own pharma-grade psilocybin with this biosynthesis technology at scale, which will be used to support its current psilocybin-based product pipeline.

“We are excited to partner with NC State and work with Dr. Williams and his team to develop a proprietary form of psilocybin that can be produced at scale for research and commercial purposes while allowing us to create our own unique product offerings with psilocybin in different delivery methods so as to treat the various mental health conditions and other diseases that psilocybin has shown to be a potential viable treatment option for.”

Michael Frank, CEO of Revive

Revive Therapeutics last traded at $0.61 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

Revive Therapeutics Conducts $10.0 Million Bought Deal Financing

Revive Therapeutics (CSE: RVV) this evening announced that it will be conducting a bought deal...

Wednesday, January 20, 2021, 08:37:25 PM

The Deep Dive Compiles Company Profile on Revive Therapeutics

The Deep Dive has assembled a company profile for that of Revive Therapeutics (CSE: RVV),...

Tuesday, May 19, 2020, 02:30:25 PM

Revive Therapeutics To Conduct Phase 1 Clinical Trials For Psilocybin

Revive Therapeutics (CSE: RVV) is driving forward with its psilocybin studies. The company announced this...

Wednesday, September 2, 2020, 08:43:51 AM

Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin

Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an...

Thursday, April 22, 2021, 08:18:53 AM

Revive Therapeutics Provides Market Update On Cannabinoid Related Research

Revive Therapeutics (CSE: RVV) this morning provided an update in connection with its ongoing cannabinoid...

Thursday, February 11, 2021, 08:01:25 AM